|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 122.00 CHF | -0.34% |
|
-3.10% | +11.31% |
| 07-14 | US FDA approves Celcuity's breast cancer drug | RE |
| 07-14 | Where would AI lead Pharma in the long run? |  |
| Market Cap | 276B 242B 223B 205B 388B 26,600B 395B 2,662B 1,044B 13,001B 1,038B 1,015B 44,812B | P/E 2026 * |
21.2x | P/E 2027 * | 17.9x |
|---|---|---|---|---|---|
| Enterprise Value | 308B 270B 249B 229B 433B 29,679B 441B 2,970B 1,165B 14,506B 1,158B 1,133B 50,000B | EV / Sales 2026 * |
5.42x | EV / Sales 2027 * | 5.06x |
| Free-Float |
91.66% | Yield 2026 * |
2.9% | Yield 2027 * | 3% |
Last Transcript: Novartis AG
| 1 day | -0.41% | ||
| 1 week | -3.10% | ||
| Current month | -3.62% | ||
| 1 month | +1.48% | ||
| 3 months | +3.09% | ||
| 6 months | +6.57% | ||
| Current year | +11.31% |
| 1 week | 121.06 |  | 125.8 |
| 1 month | 117.96 | | 128.92 |
| Current year | 107.68 | | 131 |
| 1 year | 91.2 | | 131 |
| 3 years | 81.1 | | 131 |
| 5 years | 72.84 | | 131 |
| 10 years | 65.09 | | 131 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 01/02/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 16/03/2026 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 16/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 01/01/2015 |
| Director/Board Member | 69 | 01/01/2016 | |
Ton Büchner
BRD | Director/Board Member | 61 | 01/01/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 05-18 | Sell | -5,200 | 0.0003% | |||
| 05-04 | Sell | 6,800 | 0.0003% | |||
| 02-17 | Sell | 30,743 | 0.0015% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.34% | -3.10% | +27.00% | +43.66% | 277B | |
| +0.39% | -4.72% | +50.10% | +159.07% | 1,028B | |
| -1.97% | -5.55% | +60.33% | +56.40% | 611B | |
| +1.36% | -2.22% | +32.59% | +83.30% | 432B | |
| +0.98% | -1.40% | +29.49% | +23.12% | 323B | |
| +1.63% | -11.76% | +19.72% | +23.20% | 257B | |
| +3.39% | +2.29% | -23.68% | -38.33% | 217B | |
| +0.97% | -2.50% | +22.66% | +57.47% | 192B | |
| +1.41% | -2.69% | +21.19% | +70.59% | 161B | |
| +2.12% | +2.68% | +0.35% | -31.13% | 138B | |
| Average | +1.07% | -4.64% | +23.98% | +44.73% | 363.65B | |
| Weighted average by Cap. | +0.59% | -5.28% | +34.98% | +74.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 56.91B 49.75B 45.9B 42.19B 79.94B 5,476B 81.31B 548B 215B 2,676B 214B 209B 9,225B | 60.31B 52.73B 48.64B 44.71B 84.72B 5,803B 86.17B 581B 228B 2,836B 226B 222B 9,776B |
| Net income | 14.08B 12.31B 11.36B 10.44B 19.78B 1,355B 20.12B 136B 53.19B 662B 52.87B 51.71B 2,282B | 15.64B 13.68B 12.62B 11.6B 21.98B 1,505B 22.35B 151B 59.1B 736B 58.75B 57.46B 2,536B |
| Net Debt | 32B 27.98B 25.81B 23.73B 44.96B 3,079B 45.73B 308B 121B 1,505B 120B 118B 5,188B | 28.5B 24.92B 22.99B 21.13B 40.04B 2,743B 40.72B 274B 108B 1,340B 107B 105B 4,620B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/07/26 | CHF 122.00 | -0.34% | 1,730,393 |
| 14/07/26 | CHF 122.42 | -1.73% | 2,431,098 |
| 13/07/26 | CHF 124.58 | +0.24% | 2,143,959 |
| 10/07/26 | CHF 124.28 | -0.02% | 2,334,841 |
| 09/07/26 | CHF 124.30 | -1.27% | 2,233,204 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
